Cargando…
Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer
The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a ne...
Autores principales: | Seruga, B., Gan, H.K., Knox, J.J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687807/ https://www.ncbi.nlm.nih.gov/pubmed/19478903 |
Ejemplares similares
-
Targeted therapies for renal cell carcinoma: more gains from using them again
por: Gan, H.K., et al.
Publicado: (2009) -
The contemporary role of surgery in kidney cancer
por: Lattouf, J.B., et al.
Publicado: (2009) -
Inhibition of mtor in kidney cancer
por: Kapoor, A.
Publicado: (2009) -
Role of cytokine therapy for renal cell carcinoma in the era of targeted agents
por: Koneru, R., et al.
Publicado: (2009) -
Triple Synchronous Urogenital Malignancies of the Bladder, Kidney, and Prostate: Management in a Single Operation
por: Perry, Kyler W, et al.
Publicado: (2023)